abs365.txt	background		adults	living	with	human	immunodeficiency	virus	(hiv)	are	atincreased	risk	for	anal	and	oropharyngeal	cancer	caused	by	human	papillomavirus(hpv)		the	efficacy	of	hpv	vaccines	in	this	population	is	unknown	methods		in	this	phase	3		double-blind		randomized		controlled	trial		we	assignedhiv-infected	adults	aged	≥27	years	to	the	quadrivalent	hpv	(types	6		11		16		18)vaccine	or	placebo	(1	1)	stratified	by	sex	and	presence	of	anal	high-gradesquamous	intraepithelial	lesions	on	biopsy	(bhsil)		the	primary	endpoint	wasvaccine	efficacy	against	incident	persistent	anal	infection	with	quadrivalentvaccine	types	or	single	detection	at	the	final	visit	that	were	not	present	atbaseline		secondary	endpoints	included	vaccine	efficacy	for	anal	bhsil	after	week52		persistent	oral	hpv	infection	results		a	total	of	575	participants	were	randomized		the	data	and	safetymonitoring	board	stopped	the	study	early	due	to	futility		vaccine	efficacy	was22%	(95	1%	confidence	interval	[ci]		-31%		53%)	for	prevention	of	persistent	analinfection	or	single	detection	at	the	final	visit		0%	(95%	ci	-44%		31%)	forimproving	bhsil	outcomes	and	88%	(95	1%	ci	2%		98%)	for	preventing	persistentoral	hpv	infection		but	was	32%	(95	1%	ci	-80%		74%)	for	6-month	persistent	oralhpv	infection	or	single	detection	at	the	final	visit	conclusions		these	results	do	not	support	hpv	vaccination	of	hiv-infected	adultsaged	≥27	years	to	prevent	new	anal	hpv	infections	or	to	improve	anal	hsiloutcomes		however		our	data	suggest	a	role	for	prevention	of	oral	hpv	infections	but	this	finding	should	be	confirmed	in	future	studies	clinical	trials	registration		nct01461096	
